Neurocrine Biosciences Interest Expense 2011-2025 | NBIX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Neurocrine Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	25.8 M	32.8 M	32 M	30.5 M	19.5 M	-	-	18 K	16 K	14 K	36 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
32.8 M	14 K	15.6 M

Quarterly Interest Expense Neurocrine Biosciences

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	1.1 M	-	1.1 M	1.3 M	1.1 M	-	1.2 M	2.2 M	2.6 M	-	6.6 M	6.2 M	6.4 M	-	8.5 M	8.3 M	8.2 M	-	8 M	7.9 M	7.9 M	-	7.67 M	7.59 M	7.5 M	-	7.34 M	4.77 M	-	-	-	-	-	-	-	-	-	-	-	3 K	-	-	-5 K	4 K	2 K	-	2 K	5 K	2 K	-	18 K	5 K	8 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.5 M	-5 K	3.66 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	459 K	$ 4.75	-0.94 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.05	0.16 %	$ 236 M	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 209.68	-1.47 %	$ 5 B	Danmark
Aptevo Therapeutics APVO	472 K	$ 0.6	-35.15 %	$ 166 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.16	2.1 %	$ 7.6 B	Australia
BioVie BIVI	4.3 M	$ 1.18	-7.09 %	$ 1.74 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.87	0.22 %	$ 1.3 B	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.22	25.66 %	$ 479 M	Israel
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Axon Enterprise AXON	286 M	$ 587.62	-0.6 %	$ 44.5 B	USA
Aytu BioScience AYTU	-512 K	$ 2.48	-1.98 %	$ 15.6 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Catalyst Biosciences CBIO	1.04 M	$ 12.49	0.95 %	$ 822 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Celldex Therapeutics CLDX	927 K	$ 26.14	-2.57 %	$ 1.68 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 10.86	0.51 %	$ 702 M	USA
Biogen BIIB	250 M	$ 175.92	-0.23 %	$ 25.6 B	USA
Cerevel Therapeutics Holdings CERE	10.6 M	-	-	$ 7.29 B	USA